Scientists Move Closer To Genetically Treating The Heart

May 30, 1997

Johns Hopkins cardiologists have developed a technique for efficiently delivering genes to virtually all the cells in the heart, moving prospects for gene therapy for heart diseases over an imposing barrier.

Using a disabled version of a common virus, the adenovirus, as a carrier, Hopkins researchers "infected" nearly 100 percent of the muscle cells of a rabbit heart with a new gene.

"Our novel delivery system is the first to demonstrate virtually complete transduction of an intact heart and could be adapted to achieve widespread gene transfer in human hearts," says John Lawrence, M.D., assistant professor of cardiology and principal author of a recent paper in Proceedings of the National Academy of Sciences.

Many previous attempts to use an adenovirus to deliver genes have been made by "recombining" or genetically merging a disabled virus with genetic material. Scientists rely on the virus to carry this material in when it infects a cell. Until the Hopkins experiments, though, scientists had only been able to produce local or spotty infection (or transduction) in the heart.

In initial studies in isolated heart cells, Hopkins scientists identified specific factors that enhanced transduction, such as warm heart temperature, high concentration of the virus, and prolonged exposure to the virus.

The researchers put this information to work in whole rabbit hearts kept alive temporarily in the laboratory. Using the coronary arteries, researchers delivered high concentrations of a virus carrying a "reporter" gene--a gene for an enzyme whose presence in cells they could easily detect. They also collected the virus after it had passed through the heart and redelivered it several times.

"Our infection rates more than tripled the most successful previous experiments. We came very close to infecting 100 percent of all cells," says Lawrence. "We believe that the repeated passes through the heart gave the virus time to overcome structural barriers to its spread."

Changes in the function of heart muscle cells can cause a wide variety of diseases, including congestive heart failure, which decreases the heart's ability to contract and efficiently pump blood; familial hypertrophic cardiomyopathy, an inherited condition that over-thickens the muscle of the heart; and long QT syndrome, an inherited irregularity of the heartbeat. To cure them, Lawrence notes, researchers will need to modify the characteristics of individual diseased cells in a manner that can easily be applied throughout the heart. The new technique his laboratory developed makes gene therapy a potential way to do that, he says.

Lawrence says modern cardiac surgery techniques should enable doctors to create conditions similar to the rabbit experiments in human hearts, but further animal research is needed.

To make genes that can have a beneficial effect on the heart, Lawrence notes, scientists also need to learn more about how heart cells control heart functions like contraction and rhythm.

Other authors were Kevin Donahue, Kohei Kikkawa, David Johns and Eduardo Marban. The study was supported by the Four Schools Physician-Scientist Program, the Lucille P. Markey Foundation, the Tanabe Seiyaku Co. Ltd., and the Johns Hopkins University Merck Clinician Scientist Award.
Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to or

On a POST-EMBARGOED basis find them at,, Newswise at or on CompuServe in the SciNews-MedNews library of the Journalism Forum under file extension ".JHM", Quadnet at or ScienceDaily at

Johns Hopkins Medicine

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to